CHYM trades 39.9% below Wall Street's consensus target of $30.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CHYM achieves its forward estimates and maintains a stable P/E multiple of 68.8x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Chime Financial, Inc. Class A Common Stock (CHYM) has a Wall Street consensus price target of $30.00, based on estimates from 9 covering analysts. With the stock currently trading at $21.45, this represents a potential upside of +39.9%. The company has a market capitalization of $8.59B.
Analyst price targets range from a low of $29.00 to a high of $31.00, representing a 7% spread in expectations. The median target of $30.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CHYM trades at a trailing P/E of -8.1x and forward P/E of 68.8x. Analysts expect EPS to grow +112.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SOFISoFi Technologies, Inc. | $23.9B | $18.61 | $21.40 | +15.0% | Hold | 31.2x | 27 |
DAVEDave Inc. | $5.3B | $396.00 | $351.80 | -11.2% | Buy | 24.9x | 11 |
MQMarqeta, Inc. | $1.6B | $16.83 | $8.06 | -52.1% | Hold | 433.8x | 22 |
AFRMAffirm Holdings, Inc. | $28.6B | $85.78 | $83.67 | -2.5% | Buy | 68.9x | 33 |
OPFIOppFi Inc. | $863M | $10.01 | $11.00 | +9.9% | Buy | 5.6x | 6 |
PYPLPayPal Holdings, Inc. | $39.8B | $45.09 | $50.05 | +11.0% | Hold | 8.5x | 70 |
GPNGlobal Payments Inc. | $18.3B | $77.41 | $85.45 | +10.4% | Buy | 5.6x | 62 |
NRDSNerdWallet, Inc. | $690M | $9.48 | $13.33 | +40.6% | Buy | 10.4x | 6 |
LMNDLemonade, Inc. | $6.0B | $78.70 | $71.00 | -9.8% | Buy | — | 15 |
UPSTUpstart Holdings, Inc. | $3.3B | $34.33 | $37.25 | +8.5% | Buy | 29.8x | 22 |
Quick answers to the most common questions about buying CHYM stock.
The consensus Wall Street price target for CHYM is $30, representing 39.9% upside from the current price of $21.45. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CHYM has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $30 implies 39.9% upside from current levels.
At a forward P/E of 68.8162x, CHYM trades at a premium valuation. The consensus price target of $30 (39.9% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $31 for CHYM, while the most conservative target is $29. The consensus of $30 represents the median expectation. These targets typically reflect 12-month expectations.
CHYM is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CHYM stock forecast based on 9 Wall Street analysts shows a consensus price target of $30, with estimates ranging from $29 (bear case) to $31 (bull case). The median consensus rating is "Buy".
CHYM trades at a forward P/E ratio of 68.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on CHYM, with a "Buy" consensus rating and $30 price target (39.9% upside). 8 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CHYM analyst price targets range from $29 to $31, a 7% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $30 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.